Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the appointment of Molly Harper as Chief Business Officer. Ms. Harper will provide strategic leadership to the commercial, corporate development and business development functions, and lead the planning and commercialization of Synlogic’s growing pipeline.
“We are thrilled to welcome Molly to Synlogic. Molly’s appointment could not come at a better time given our recent encouraging interim analysis data in our PKU program, and our intention to begin a pivotal program in PKU in 2022. Her deep experience in developing and commercializing meaningful therapies for patients and building strategic partnerships will further strengthen our leadership team,” said Aoife Brennan, M.B. Ch.B., Synlogic’s president and Chief Executive Officer.
Recommended AI News: Huobi Ventures Announces Investment in Project SEED, a One-Stop, Play-to-Earn GameFi Platform
“I am delighted to join Synlogic on the cusp of an incredible opportunity to bring forward a meaningful new therapy for patients with PKU. The recent proof of concept in PKU demonstrates the potential for Synthetic Biotic medicines to positively impact patient lives,” said Molly Harper, Chief Business Officer. “I look forward to working with the Synlogic team, the patient community, and our industry partners to translate a compelling pipeline into meaningful new therapies for patients.”
Recommended AI News: PortAventura World Becomes the First Theme Resort to Accept Bitcoin as Payment at the Hotels Next Season
Ms. Harper is an experienced biotech leader with a demonstrated track record of translating development assets into commercialized products. Ms. Harper joins Synlogic from Relmada Therapeutics, Inc. where she served as Executive Vice President of Operations. Prior to Relmada she served in positions of increasing responsibility with Akcea Therapeutics, including most recently as Senior Vice President and Global Franchise General Manager, with responsibility for a six-drug portfolio, including the commercialization of two rare disease drugs. Ms. Harper was also Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme, having previously served at various positions in sales and marketing with Merck & Co, and equity research at UBS Warburg.
Recommended AI News: Red Box Compliance Recording Solution is Certified for Microsoft Teams
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.